Comparative Evaluation of Various Combinable Magnetic Resonance (CMR) Pulse-sequences for Macrophage Imaging Using Ferucarbotran

Robert Bosch Gesellschaft für Medizinische Forschung mbH

Status and phase: Completed; Phase 3; Phase 2

Conditions: Acute Myocardial Infarction

Treatments: Drug: Ferucarbotran (Resovist)

Study type: Interventional

Funder types: Other

Identifiers

NCT00886444

RBK-143

NIMINI-1

Details and patient eligibility

About

The aim of this study is to:

• clarify whether macrophage imaging using ferucarbotran is able to delineate the region of myocardial infarction as accurate as gadolinium-based necrosis/fibrosis imaging;
• identify possible differences in infarct imaging using ferucarbotran for macrophage imaging compared to necrosis/fibrosis imaging with gadolinium-based compounds; and
• evaluate which MRI pulse-sequences maximise sensitivity for macrophage imaging with ferucarbotran in the setting of acute myocardial infarction.

Enrollment: 20 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• acute myocardial infarction (STEMI or NSTEMI)

Exclusion criteria

• contraindication to CMR or Magnevist® or Resovist®

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

20 participants in 1 patient group

Ferucarbotran

Experimental group

Treatment:

Drug: Ferucarbotran (Resovist)